Drugs / CD34+ Hematopoietic Progenitor Cells
last change Dec 2023 re-read 2 minutes ago

CD34+ Hematopoietic Progenitor Cells

also known as HSPC

Cell therapy

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01660607 Background Feb 2012 → Dec 2023 acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome Stanford University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD34+ Hematopoietic Progenitor Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660607
Known as HSPC “CD34+ Hematopoietic Progenitor Cells (HSPC)” NCT01660607
Modality Cell therapy “Biological: CD34+ Hematopoietic Progenitor Cells (HSPC)” NCT01660607